Bioshares Biotech Clinical Trials Fd

Erasca Executives Discuss Clinical Data and R&D Pipeline of ERAS-0015

Eli Lilly's Acquisition of Ventyx Biosciences Receives Early Termination Notice

Tango Therapeutics Inc. CFO Reports Disposal of Common Stock

Erasca Inc. CFO and CBO David M. Chacko Buys Company's Common Stock

Erasca (ERAS) Files for a $150 Million IPO and Offers Over-Allotment Option to Underwriters

Erasca Reports Total Cash and Equivalents of Approximately $341.8 Million

Definium Therapeutics Launches LSD Promotion Campaign for Psychiatry

Enliven Therapeutics' Leukemia Candidate ELVN-001 Shows Positive Clinical Trial Results

Eli Lilly Agrees to Acquire Ventyx Biosciences for $1.2 Billion to Expand Drug Pipeline

HC Wainwright Upgrades Erasca's 2027 Fiscal Year Profit Forecast and Maintains Buy Rating

RAPT Therapeutics Showcases ozureprubart Progress at JPM Healthcare and Secures Financing

Insiders make a multi-million dollar investment in Alumis Inc.

Enliven Therapeutics Inc. COO Reports Disposal of Common Stock

HC Wainwright Raises Erasca's Target Price to $11

Foresite Capital Management VI LLC and related entities acquire Alumis Inc. common stock

James B. Tananbaum Acquires Shares in Alumis Inc

Erasca Announces Cancer Elimination Strategy, Focusing on RAS/MAPK Pathway

LifeSci Capital analyst maintains hold rating on Ventyx Biosciences

Alumis Inc. Reports Q4 Earnings Miss

Alumis Reports Preliminary Financials and Plans Stock Issuance

Jiade

Algorhythm

Moolec Science SA

Founder

Nuveen Real Asset Income and Growth Fund

GraniteShares 2x Long RIVN Daily ETF

Atomera

Corsair Gaming

Vivopower

Phio Pharmaceuticals

SBIO

WAVE Life Sciences insider Chris Francis sold 1,883 shares at $13.45 each, totaling $25,326.35, reducing his stake by 2.95% to 61,867 shares valued at $832,111.15. The transaction was disclosed to the SEC. The stock has seen a recent decline, trading down 2.4% to $13.27. Analysts have mixed ratings, with price targets ranging from $22.00 to $43.00, and a consensus rating of "Moderate Buy."

Market Beat

iShares US Pharma

Health Care Select Sector SPDR

SPDR Pharmac

ALPS Medical Breakthrough

Wave Life Sciences

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VG Health

VanEck Biotech ETF

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 1,883 Shares of Stock

IBBQ

Wave Life Sciences shares rose 3.6% to $13.40 after regaining full rights to its genetic disorder therapy, WVE-006, from GSK. The company plans to seek accelerated approval from the US FDA, with feedback expected by mid-2026. WVE-006 targets alpha-1 antitrypsin deficiency, a genetic disorder affecting lung and liver health. Ongoing clinical trial data is anticipated in Q1 2026. Analysts suggest GSK's decision was strategic rather than data-driven, as they focus on larger indications like COPD. Wave Life's stock increased 37.4% last year.

Reuters

Invesco Nasdaq Biotechnology ETF

BUZZ-Wave Life rises after regaining full rights to genetic disorder therapy from GSK

WAVE Life Sciences Ltd plans to accelerate regulatory engagement for WVE-006, targeting an accelerated approval pathway with the FDA. Regulatory feedback is expected by mid-2026, with data from a 400 mg cohort anticipated in Q1 2026 and data from 600 mg cohorts expected later in 2026. The company expects to have sufficient cash runway into the third quarter of 2028.

Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006

Wave Life Sciences Ltd. and GSK are advancing their collaboration on oligonucleotide therapies using Wave’s PRISM® platform. GSK has selected a fourth program for development, allowing for up to eight programs under their partnership. Wave could receive up to $2.8 billion in milestone and royalty payments as these programs progress, with ongoing target validation and anticipated payments in 2026 and beyond.

GlaxoSmithKline plc

Wave Life Sciences and GSK Advance Oligonucleotide Therapeutics Collaboration

MOSCOW, Dec 19 (Reuters) - Russian President Vladimir Putin told his annual end-of-year press conference on Friday that U.S. President Donald Trump was right to sue the BBC over edited clips of his speech.Trump sued Britain’s publicly owned broadcaster for at least $10 billion in damages over edited clips of a speech that made it appear he directed supporters to storm the U.S. Capitol. The BBC has apologised to Trump and has said it will defend the case.

Putin says Trump is right to sue BBC over speech edit

President Trump has filed a $5 billion defamation lawsuit against the BBC over an edited January 6 speech in a Panorama documentary. The BBC apologized for the edit but denied defamation, and the case could influence how global media handles politically sensitive reporting. The post Trump Sues BBC for $5B Over Edited January 6 Speech in Panorama Film first appeared on The Shib Daily. source:

CoinLive

Trump Sues BBC for $5B Over Edited January 6 Speech in Panorama Film

Donald Trump has filed a $10bn lawsuit against the BBC in Florida, alleging misleading edits in a Panorama documentary. The lawsuit claims BBC producers filmed at Mar-a-Lago and cites jurisdiction due to BBC's Florida office. Trump's legal team argues the BBC acted with malice, seeking damages of at least $5bn. The BBC has not responded, and the case may reveal more about Trump's January 6 statements.

cityam

Trump sues BBC for $10bn in Florida, citing producers trips to Mar-a-Lago

A UK minister supports the BBC's decision to stand firm against Donald Trump's defamation lawsuit. Trump sued the BBC over edited clips related to the January 6 Capitol attack. The BBC apologized for editing errors but maintains there's no legal basis for Trump's claim. Junior health minister Stephen Kinnock stated the BBC is right to defend its position.

UK minister urges BBC to stand firm against Trump lawsuit

Former President Donald Trump has filed a defamation lawsuit against the BBC, seeking $10 billion in damages. The lawsuit claims the BBC edited clips of his January 6, 2021 speech to falsely suggest he incited violence at the U.S. Capitol. The BBC admitted an error in judgment but denies the legal basis for the lawsuit. The controversy has led to a crisis at the BBC, including the resignation of two senior officials. Trump's lawsuit alleges significant reputational and financial harm.

Trump sues the BBC for defamation over editing of January 6 speech, seeks up to $10 billion in damages

Court documents show that Trump is suing the BBC for defamation over a clip of his January 6 speech, seeking $5 billion in damages from the BBC

Wallstreetcn

Trump suing BBC for $5 billion - court document

marketscreener

Trump Media & Tech

Trump suing BBC for $5 billion - court document

Trump sues BBC for defamation. (POLITICO)

US President Donald Trump announced plans to sue the BBC over its editing of his 2021 Capitol speech, claiming it misrepresented his words. The lawsuit, seeking billions in damages, may be filed by Tuesday. The BBC acknowledged an error in judgment and apologized but denied legal liability. Trump has a history of suing media for perceived bias. The BBC documentary in question was not broadcast in the US.

南华早报

Trump to sue UK’s BBC over Panorama edit of 2021 Capitol speech ‘by Tuesday’

Sir Keir Starmer plans to discuss BBC's standards with Donald Trump, who intends to sue the broadcaster for up to $5bn over a doctored speech. Despite BBC's apology, Trump claims defamation, leading to resignations within the corporation. The event underscores media integrity and political influence concerns.

Yahoo Finance

BBC must get its house in order, Starmer to tell Trump

US President Donald Trump plans to sue the BBC for up to $5 billion over a documentary that allegedly misrepresented his speech from January 6, 2021. The BBC admitted to editing errors but rejected defamation claims. The incident led to resignations of senior BBC leaders amid accusations of bias. Trump demands an apology and compensation, claiming reputational harm. The BBC apologized but won't rebroadcast the documentary. The controversy has sparked debate over the BBC's impartiality and funding, with concerns about using public money for potential damages.

Trump to sue BBC for up to US$5 billion: ‘they’ve even admitted they cheated’

Bioshares Biotech Clinical Trials Fd(BBC.US)

Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Insider Sells 1,883 Shares of Stock

BUZZ-Wave Life rises after regaining full rights to genetic disorder therapy from GSK

Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006

Wave Life Sciences and GSK Advance Oligonucleotide Therapeutics Collaboration

Putin says Trump is right to sue BBC over speech edit